Key points are not available for this paper at this time.
Chimeric antigen receptor (CAR) T cells targeting CD22 (CD22-CAR) provide a therapeutic option for patients with CD22
Share your take
Add a clinician perspective alongside expert commentary.
Schultz et al. (2024) studied this question.